Abstract | BACKGROUND: METHODS: A structured ten-question online survey was sent to all colorectal surgeons, with three questions on clinical experience and demographics, one on health economics and six on hypothetical clinical scenarios. Scores were collated and reported based on Likert scales. RESULTS: Eighty-one respondents (36.2%) completed the survey. Most surgeons (66.7%) strongly disagreed with offering CRS and HIPEC at all hospitals. The majority (87.7%) agreed that CRS and HIPEC offered a higher survival benefit than systemic chemotherapy in pseudomyxoma peritonei (PMP), and 69.1% in CRPM (comparators: 60.5% ovarian cancer, 14.8% gastric cancer). There were mixed strategies in managing low-volume, isolated peritoneal recurrences. The majority did not recommend second-look laparoscopy, but favoured operative management of Krukenberg tumours. In the presence of incidental peritoneal metastases, only 29.6% favoured biopsy only and referring the patient to a peritoneal disease centre. CONCLUSIONS: Response rate was relatively low. In Australia and New Zealand, colorectal surgeons see a strong role for CRS and HIPEC in the management of PMP and CRPM. The role of " second look" surgery in high-risk cases is controversial and not supported. Krukenberg tumours are viewed as surgical disease. Regular updates and collaboration with peritoneal centres may help surgeons stay abreast with latest evidence in the field.
|
Authors | Vignesh Narasimhan, Satish Warrier, Michael Michael, Jacob McCormick, Robert Ramsay, Craig Lynch, Alexander Heriot |
Journal | Pleura and peritoneum
(Pleura Peritoneum)
Vol. 4
Issue 4
Pg. 20190022
(Dec 01 2019)
ISSN: 2364-768X [Electronic] Germany |
PMID | 31799373
(Publication Type: Journal Article)
|
Copyright | © 2019 Narasimhan et al., published by De Gruyter. |